Therefore, we prospectively evaluated the efficacy and safety of osimertinib and bevacizumab cotreatment in patients with EGFR-mutated advanced NSCLC with pleural or pericardial effusion who had not previously received systemic chemotherapy for advanced disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.